European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) — Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”),…